(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 March 2011 (31.03.2011)

PCT

(10) International Publication Number
WO 2011/038185 A2

(51) International Patent Classification:
C07D 487/14 (2006.01)

(21) International Application Number:
PCT/US2010/050132

(22) International Filing Date:
24 September 2010 (24.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/245,769 25 September 2009 (25.09.2009) US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **CHARRIER, Jean-Damien** [FR/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DURRANT, Steven** [GB/GB]; Unit 88 Milton Park, Abingdon, Oxfordshire OX 14 4RY (GB). **KAY, David** [GB/GB]; Unit 88, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(74) Agent: **LIM, Booyong, S.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

[Continued on next page]


(54) Title: METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS



(I)



(A)



(B)

(57) Abstract: A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the step of: a) cyclizing a compound represented by Structural Formula (A) under suitable reductive cyclisation conditions to form a compound represented by Structural Formula (B) wherein R^{10} is LG_1 or $-X^1R^1$, and $-LG_1$ is a suitable leaving group; and b) optionally, when R^{10} of Structural Formula (B) is LG_1, further comprising the step of replacing the $-LG_1$ of Structural Formula (B) with $-X^1R^1$ to form the compound represented by Structural Formula (I).

WO 2011/038185 A2

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*